Podcast: Play in new window | Download
In this episode of TSC Now, host Dan Klein celebrates Worldwide LAM Awareness Month (#WWLAM) and raises awareness of lymphanhgioleiomyomatosis (LAM) and a pivotal clinical trial in LAM that is enrolling right now.
Dan interviews Frank McCormack, MD, Professor and Director of the Division of Pulmonary, Critical Care and Sleep Medicine at University of Cincinnati and former Scientific Director of The LAM Foundation for 25 years. Dr. McCormack is the lead investigator for the Multicenter Interventional Lymphangioleiomyomatosis Early Disease (MILED) Trial, designed to answer the question of whether we should be starting sirolimus at low doses earlier in the course of LAM, before symptoms develop and while lung function is still normal, similar to the manner in which we treat diabetes and high blood pressure early to prevent future heart and kidney complications..
Dr. McCormack shares how the previous MILES trial which led to the approval of sirolimus for the treatment of LAM in 2015 gave women a safe and effective treatment and created the foundation for the current trial looking at whether earlier intervention may potentially prevent serious loss of lung function for women with LAM. He shares the eligibility criteria for the trial, the risks and benefits of participation and how those interested in participating can enroll. He also discusses the future of LAM research and how new tests, preclinical models and drug candidates are needed to accelerate therapies that don’t just impede the growth of LAM cells, but actually kills the cells to help restore lost lung function.
Researchers are currently seeking 10 additional participants for the MILED Trial.
You may be eligible if you:
- Are an adult woman with LAM
- Have an FEV1 greater than 70% predicted
- Are not currently taking sirolimus
During the study, participants will:
- Attend 8 study visits over 2 years (about one visit every 4 months)
- Complete blood tests, a physical exam, and pulmonary function tests at visits
- Answer questions about breathing, fatigue and quality of life
- Take one capsule every day (1 mg sirolimus or a sugar pill) throughout the study
- Record their pill taking and any side effects in an electronic diary
Participants will receive:
- Physical exams, pulmonary function tests, a chest x-ray, and laboratory tests free of charge
- Study drug (either 1 mg sirolimus or placebo) throughout the study
- Reimbursement for travel expenses to attend each study visit
To get more information or to see if you may be eligible, please contact Susan McMahan Sellers, BSN, RN at SUSAN.MCMAHAN@UC.EDU or by calling 513-558-4376.
Resources and Links
- Learn more about the MILED trial at clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03150914
- Learn about the trial on The LAM Foundation’s website: https://www.thelamfoundation.org/miled
- Learn more about #WWLAM: https://thelamfoundation.org/WorldwideLAMAwarenessMonth
- Learn more about LAM in TSC: https://www.tscalliance.org/about-tsc/signs-and-symptoms-of-tsc/lungs/
This podcast is sponsored by: